EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Shining the PSMA spotlight on peritoneal metastases in prostate cancer

Jonathan Kuten iD, Stephanie Chahwan, Charlie White, Audrey Mauguen iD, Heiko Schöder iD, Simone Krebs iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-05 · 53 (6) · 3552-3561

DOI: 10.1007/s00259-025-07703-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 11.12.2025. Verfasst von Jonathan Kuten und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. k…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Peritoneal Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to retrospectively characterize patients with biochemical failure and peritoneal metastases detected by PSMA PET/CT, describe the detectability of 18 F-FDG PET/CT and conventional imaging; and assess patient outcome.

Methods

We searched an institutional database for patients who underwent 68 Ga-PSMA-11 or 18 F-DCFPyL PET/CT between 5/2016 and 9/2024 and measured the SUVmax of the most avid peritoneal lesion. We assessed correlative CT, MRI, or FDG PET/CT performed within 90 days and validated peritoneal metastases via composite reference. Survival was estimated with Kaplan-Meier analysis. Seven patients subsequently treated with 177 Lu-PSMA-617 were analyzed.

Results

Of 9,877 screened patients, peritoneal metastases were confirmed in 57. Most had Gleason ≥ 4 + 3 (81%) and median PSA was 10.0 ng/ml (range 0.34–1,304); 54% were castration-sensitive. Isolated peritoneal disease occurred in 19 (33%). The median SUVmax was 8.2. Among 29 patients with correlative CT/MRI, 41% were negative. Of 14 patients with correlative FDG PET/CT; 43% demonstrated FDG-avid peritoneal disease. On follow-up ( n = 42), peritoneal disease improved in 38%. Of those with isolated peritoneal metastases and follow-up data ( n = 12), 58% improved. Median overall survival from detection was 53 months (95% CI: 29–not reached), and associated with lower PSA, fewer peritoneal lesions, and non-castration resistance. All seven patients treated with 177 Lu-PSMA-617 progressed.

Conclusion

Peritoneal metastases from prostate cancer are rare. Nevertheless, PSMA-avid peritoneal lesions may represent metastatic spread from prostate cancer, even in the absence of systemic disease. FDG PET/CT and CT/MRI often miss peritoneal metastases. Peritoneal disease does not necessarily indicate poor prognosis, particularly when isolated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPeritoneal NeoplasmsPositron Emission Tomography Computed TomographyRetrospective StudiesKaplan-Meier EstimateRadiopharmaceuticalsGallium IsotopesGallium RadioisotopesNeoplasm GradingFluorodeoxyglucose F18LutetiumProstate-Specific AntigenPrognosisHumansMaleMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

177Lu-PSMA-617FDG PET/CTPSMA PET/CTPeritoneal metastasesProstate cancer

Substanzen

gallium 68 PSMA-11RadiopharmaceuticalsGallium IsotopesGallium RadioisotopesFluorodeoxyglucose F18lutetium (177Lu) vipivotide tetraxetanLutetiumProstate-Specific Antigen

Autor:innen und Institutionen

  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. kutenj@mskcc.org.
  • Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Institute of Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Jonathan Kuten, Audrey Mauguen, Heiko Schöder, Simone Krebs

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Kuten, J., Chahwan, S., White, C., Mauguen, A., Schöder, H., & Krebs, S. (2026). Shining the PSMA spotlight on peritoneal metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(6), 3552-3561. https://doi.org/10.1007/s00259-025-07703-3

Vancouver

Kuten J, Chahwan S, White C, Mauguen A, Schöder H, Krebs S. Shining the PSMA spotlight on peritoneal metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(6):3552-3561. doi:10.1007/s00259-025-07703-3

BibTeX
@article{Kuten2026,
  author = {Kuten, Jonathan and Chahwan, Stephanie and White, Charlie and Mauguen, Audrey and Schöder, Heiko and Krebs, Simone},
  title = {Shining the PSMA spotlight on peritoneal metastases in prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {6},
  pages = {3552--3561},
  doi = {10.1007/s00259-025-07703-3}
}
Kostenlos starten →